Security Snapshot

LENZ Therapeutics, Inc. - Common Stock (LENZ) Institutional Ownership

CUSIP: 52635N103

13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

160

Shares (Excl. Options)

35,070,610

Price

$16.00

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
LENZ on Nasdaq
Shares outstanding
31,240,118
Price per share
$9.17
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
35,070,610
Total reported value
$561,546,515
% of total 13F portfolios
0%
Share change
+5,451,971
Value change
-$86,155,688
Number of holders
160
Price from insider filings
$9.17
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • LENZ - LENZ Therapeutics, Inc. - Common Stock is tracked under CUSIP 52635N103.
  • 160 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 160 to 7 between Q4 2025 and Q1 2026.
  • Reported value moved from $561,546,515 to $14,511.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 160 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 52635N103?
CUSIP 52635N103 identifies LENZ - LENZ Therapeutics, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of LENZ Therapeutics, Inc. - Common Stock (LENZ) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 14% -10% $198,668,637 +$209,610 4,265,106 +0.11% RA Capital Management, L.P. 05 Nov 2025
FMR LLC 12% -21% $59,243,480 -$9,208,416 3,702,718 -13% FMR LLC 31 Dec 2025
Squarepoint Ops LLC 5.1% $14,897,009 1,593,246 Squarepoint Ops LLC 01 Apr 2026
BlackRock, Inc. 4.9% -4% $24,603,568 +$1,517,744 1,537,723 +6.6% BlackRock, Inc. 31 Dec 2025
Point72 Asset Management, L.P. 4.8% $63,244,042 1,357,751 Steven A. Cohen 30 Sep 2025
Paradigm Biocapital Advisors LP 3.8% -28% $50,001,813 -$16,133,961 1,073,461 -24% Paradigm BioCapital Advisors LP 30 Sep 2025
Versant Venture Capital VI, L.P. 3.4% -18% $48,936,901 -$6,192,532 1,050,599 -11% Versant Venture Capital VI, L.P. 05 Nov 2025

As of 31 Dec 2025, 160 institutional investors reported holding 35,070,610 shares of LENZ Therapeutics, Inc. - Common Stock (LENZ). This represents 112% of the company’s total 31,240,118 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of LENZ Therapeutics, Inc. - Common Stock (LENZ) together control 93% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 13% 4,178,823 0% 0.69% $66,861,168
FMR LLC 12% 3,702,718 +4141% 0% $59,243,480
Alpha Wave Global, LP 12% 3,612,211 0% 7.1% $57,795,376
Versant Venture Management, LLC 8.5% 2,656,888 0% 28% $42,510,208
BlackRock, Inc. 5.4% 1,692,006 +15% 0% $27,072,096
UBS Group AG 5% 1,571,738 +31% 0% $25,147,808
VANGUARD GROUP INC 4.2% 1,321,202 -0.68% 0% $21,139,232
FRANKLIN RESOURCES INC 3.5% 1,096,334 +87% 0% $17,541,344
PRICE T ROWE ASSOCIATES INC /MD/ 3.3% 1,023,542 +308% 0% $16,378,000
72 Investment Holdings, LLC 3.3% 1,017,751 0% 32% $16,284,016
TANG CAPITAL MANAGEMENT LLC 2.8% 865,169 -3.6% 0.68% $13,842,704
INTRINSIC EDGE CAPITAL MANAGEMENT LLC 1.8% 569,705 1.8% $9,115,280
MILLENNIUM MANAGEMENT LLC 1.7% 539,348 0.01% $8,629,568
STATE STREET CORP 1.6% 510,749 +22% 0% $8,171,984
C WorldWide Group Holding A/S 1.6% 500,000 0.14% $8,000,000
Squarepoint Ops LLC 1.6% 491,898 +448% 0.02% $7,870,368
Aberdeen Group plc 1.6% 489,432 +274% 0.01% $7,830,912
Alyeska Investment Group, L.P. 1.5% 463,495 +91% 0.02% $7,415,920
GEODE CAPITAL MANAGEMENT, LLC 1.5% 461,075 +1.4% 0% $7,378,622
Granahan Investment Management, LLC 1.4% 431,100 +125% 0.3% $6,897,600
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 1.3% 398,566 0% 0.01% $6,377,000
Candriam S.C.A. 1.2% 374,932 +64% 0.03% $5,999,167
PRIMECAP MANAGEMENT CO/CA/ 1.2% 372,200 0% $5,955,200
TWO SIGMA INVESTMENTS, LP 0.94% 293,446 +388% 0.01% $4,695,136
Vestal Point Capital, LP 0.88% 275,000 0.16% $4,400,000

Institutional Holders of LENZ Therapeutics, Inc. - Common Stock (LENZ) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,578 $14,511 -$1,406,028 $9.17 7
2025 Q4 35,070,610 $561,546,515 -$86,155,688 $16.00 160
2025 Q3 29,140,610 $1,355,578,952 +$224,909,861 $46.58 166
2025 Q2 24,727,156 $725,109,733 +$107,969,187 $29.31 113
2025 Q1 21,072,237 $541,761,121 +$29,092,976 $25.71 105
2024 Q4 19,863,850 $573,239,116 +$35,341,897 $28.87 94
2024 Q3 18,735,645 $444,795,067 -$1,423,016 $23.74 78
2024 Q2 18,913,542 $327,016,869 +$45,118,057 $17.29 63
2024 Q1 16,171,755 $361,085,230 +$360,723,016 $22.33 54